Clinical trials: Drug Eluting Stents
Coronary Disease
Safety and Efficacy Study of the Nile PAX Drug-Eluting Coronary Bifurcation Stent
The purpose of this trial is to assess the safety and efficacy of the Nile PAX® Drug Eluting Coronary Bifurcation Stent System for the treatment of single de novo bifurcation lesions in native coronary arteries with a main branch…
- Trial name
- BIPAX (NCT01308229)
- Testing
- Nile PAX® paclitaxel-eluting coronary stent
- Where
- 10 sites in Brazil, Bulgaria and 5 more
- Volunteers
- 102 people
- Sponsor
- MINVASYS
Coronary Artery Disease
Comparison of 1 Month vs. 12 Months DAPT in Patients Undergoing PCI With Genoss® DES
This study is a prospective, open-label, multicenter, randomized clinical trial to evaluate the efficacy of 1 month dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel followed by clopidogrel monotherapy, compared with…
- Trial name
- GENOSS-DAPT (NCT05770674)
- Testing
- 1 Month vs. 12 Months DAPT
- Where
- South Korea
- Volunteers
- 2,186 people
- Sponsor
- Kiyuk Chang
Coronary Artery Disease
Drug-Eluting Balloon in Stable and Unstable Angina
The purpose of this study is to compare DEB with BMS in CAD patients who are at high risk of bleeding and in whom the use of DES is therefore avoided.
- Trial name
- DEBUT (NCT01781546)
- Testing
- drug-eluting balloon (DEB), bare-metal stent (BMS)
- Where
- 4 sites in Finland
- Volunteers
- 220 people
- Sponsor
- North Karelia Central Hospital
Coronary Artery Disease, Myocardial Ischemia
Safety and Efficacy Study of the Amaranth Medical APTITUDE Bioresorbable Drug-Eluting Coronary Stent
The purpose of this study is to evaluate the safety and performance of a new version of a coronary artery stent for treating blockages in the arteries supplying blood to the heart muscle.
- Trial name
- RENASCENT II (NCT02568462)
- Testing
- AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
- Where
- 12 sites in Colombia, Italy
- Volunteers
- 60 people
- Sponsor
- Amaranth Medical Inc.
Acute ST Segment Elevation Myocardial Infarction
ABSORB STEMI: the TROFI II Study
This is a Prospective, randomized (1:1), active control, single-blind, non-inferiority, European multicenter clinical trial. The primary objective of this study is to assess the neointimal healing score (as evaluated by…
- Trial name
- NCT01986803
- Testing
- Percutaneous Coronary Intervention
- Where
- 8 sites in Denmark, Netherlands and 2 more
- Volunteers
- 191 people
- Sponsor
- ECRI bv
Coronary Artery Disease
The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)
The purpose of this study is to assess the safety and effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 34 mm in length (by…
- Trial name
- NCT01665053
- Testing
- PROMUS Element Plus, SYNERGY
- Where
- 126 sites in United States, Australia and 14 more
- Volunteers
- 1,684 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
Drug-Coated Balloon in Anticoagulated and Bleeding Risk Patients Undergoing PCI
The purpose of this study is to compare DCB with DES in stable CAD or ACS patients who are at high risk of bleeding. The hypothesis of the DEBATE trial is that the strategy using DCB and a shorter DAPT regimen is non-inferior to…
- Trial name
- DEBATE (NCT04814212)
- Testing
- Percutaneous coronary intervention using drug-coated balloon, Percutaneous coronary intervention using drug-eluting stent
- Where
- 14 sites in Finland, France and 2 more
- Volunteers
- 546 people
- Sponsor
- North Karelia Central Hospital
Stent Thrombosis
PeriOperative Bridging - Perioperative Anticoagulation in the Setting of Recent Intracoronary Drug Eluting Stents
The purpose of this study is to determine if an intravenous (IV) antiplatelet medication is as safe and effective at preventing clot formation in your stented artery as compared in people who have stopped clopidogrel prior to…
- Trial name
- NCT00606151
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The Cleveland Clinic
Atrial Fibrillation (AF), Coronary Artery Disease
OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation
The OPTIA-AF trial is a prospective, multicenter randomized controlled trial designed to evaluate a rhythm-guided antithrombotic strategy in patients with atrial fibrillation (AF) who maintain durable sinus rhythm after catheter…
- Conditions
- Atrial Fibrillation (AF), Coronary Artery Disease, Drug-eluting Stent
- Trial name
- OPTIA-AF (NCT07496281)
- Testing
- Oral anticoagulation, Single antiplatelet therapy
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Ewha Womans University Mokdong Hospital
Intracranial Arteriosclerosis, Stroke (CVA) or TIA
Evaluating the Safety and Efficacy of the Maurora® DES in ICAS
The purpose of the RCT trial is to evaluate whether implantation of drug-eluting stent (DES) is more efficacious than bare metal stent (BMS) in prevention of in-stent restenosis (ISR) and improvement of outcomes for symptomatic…
- Trial name
- Maurora ICAS (NCT05719883)
- Testing
- Maurora® Sirolimus Eluting Stent System, APOLLO™ Intracranial Stent System
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Beijing Tiantan Hospital
Coronary Artery Disease, Diabetes Mellitus
Outcome of Second Generation Drug-eLuting Stents in Patients With Diabetes Mellitus
Design: prospective, randomized, multi-center trial comparing the safety and efficacy in the prevention of target lesion failure (TLF) of second generation paclitaxel- versus ABT578- versus Everolimus- eluting stents Study…
- Trial name
- OCELOT (NCT01293773)
- Testing
- Taxus Element stent, Integrity Resolute stent, Xience Prime stent
- Where
- 2 sites in Italy
- Sponsor
- Policlinico Casilino ASL RMB
Peripheral Vascular Disease
Zilver PTX Delivery System
The objective of this study is to evaluate the performance of the Zilver PTX stent thumbwheel delivery system.
- Trial name
- NCT02271529
- Testing
- Zilver® PTX® Drug-Eluting Peripheral Stent
- Where
- 6 sites in Australia, Germany and 1 more
- Volunteers
- 40 people
- Sponsor
- Cook Group Incorporated
Ischemic Heart Disease
Registry in Korea: BioMimeTM Stent, Ultimaster® Stent vs. Xience® Stent
Comparison of safety and long-term effects of BioMimeTM stent and Ultimaster® stent with Xience® stent
- Trial name
- SMARTDESK-MX (NCT02986295)
- Testing
- BioMimeTM Stent, Ultimaster® Stent
- Where
- South Korea
- Volunteers
- 2,000 people
- Sponsor
- Hyeon-Cheol Gwon
Coronary Artery Disease
The ENDEAVOR Pharmacokinetic (PK) Registry: The Medtronic Endeavor Drug Eluting Coronary Stent System
The purpose of this study is to evaluate the pharmacokinetics (PK) and safety associated with ABT-578 administered using the Medtronic Endeavor Drug Eluting Coronary Stent system in the treatment of single de novo lesions in…
- Trial name
- ENDEAVOR PK (NCT00314275)
- Testing
- Coronary Artery Stenting, Endeavor
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Medtronic Vascular
Myocardial Infarction, Cardiovascular Disease
Randomized, Open Label Trial of 6 Months Versus 12 Months DAPT After Drug-Eluting Stent in STEMI
OBJECTIVE OF THE STUDY: To test the hypothesis that 6 months DAPT (Dual anti-platelet therapy) after second generation DES (Drug Eluting Stent) implantation in STEMI (ST elevation Myocardial Infarction) is not inferior to 12…
- Trial name
- DAPT-STEMI (NCT01459627)
- Testing
- 6 months DAPT, 12 months DAPT
- Where
- 16 sites in Netherlands, Norway and 2 more
- Volunteers
- 1,100 people
- Sponsor
- Maasstad Hospital
Restenosis
The ITALIC Study: Is There A LIfe for Drug-eluting Stents (DES) After Discontinuation of Clopidogrel
Background Drug-eluting stents (DES) have been extremely successful in reducing restenosis and the need for repeat revascularization procedures in patients who undergo PCI.
- Trial name
- ITALIC (NCT00780156)
- Where
- France
- Volunteers
- 1,235 people
- Sponsor
- French Cardiology Society
Coronary Disease, Coronary Artery Disease
XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study
XIENCE V® India is a prospective, open-label, multi-center, observational, single-arm study to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- XIENCE V India (NCT00631228)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent
- Where
- 18 sites in India
- Volunteers
- 1,000 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
PITT PCI Xience Registry
Stents are devices utilized to treat cholesterol blockages of the coronary (heart) arteries. The introduction of drug-eluting (coated) stents into clinical practice is regarded as a revolutionary breaktrhough, as it has reduced…
- Trial name
- NCT01299207
- Where
- United States
- Volunteers
- 2,506 people
- Sponsor
- University of Pittsburgh
Coronary Disease
Drug-eluting-stents for Unprotected Left Main Stem Disease (ISAR-LEFT-MAIN)
The purpose of this study is to evaluate the efficacy of sirolimus- and paclitaxel-eluting stents for treatment of unprotected left main coronary artery disease.
- Trial name
- NCT00133237
- Testing
- Sirolimus-eluting stent, Paclitaxel-eluting stent
- Where
- 2 sites in Germany
- Volunteers
- 607 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Drug-eluting Stent (DES)
Aspirin Mono Therapy 12-months After Drug-eluting Stents Implantation
The purpose of this study is to determine whether high dose statin therapy in patients with aspirin mono antiplatelet therapy who had received drug-eluting stent (DES) previously and were free of the adverse cardiac events during…
- Trial name
- statin (NCT01557075)
- Testing
- Atorvastatin (High dose statin treatment), Pravastatin (High dose statin treatment)
- Where
- South Korea
- Volunteers
- 2,000 people
- Sponsor
- Yonsei University